Tango Therapeutics Investor Presentation — February 2022

Document content

Confidential | 1

Targeting tumor suppressor loss

to unmask vulnerabilities in cancer

for the next generation of precision medicines

February 2022Confidential | 2

Disclaimer and Safe Harbor Statement

Certain statements in this presentation may be considered forward -looking statements. Forward -looking statements generally relat e to future events, Tango’s future financial and operating performance, goals, expectations,

beliefs, development plans and development objectives for Tango’s product pipeline. In some cases, you can identify forward -looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “path”,

“achievable”, “milestones”, “goal”, “forecast”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, statements

concerning the following include or constitute forward -looking statements: Tango has a sustainable pipeline of novel drugs and d rug programs; the Company has multiple drug candidates planned for 2022; TNG908 is a

potentially first in class PRMT5 inhibitor that is synthetic lethal with MTAP deletion; the expected timing of: (i) developme nt candidate declaration for certain targets, (ii) initiating IND -enabling studies; (iii) filing INDs, (iv)

clinical trial initiation and (v) the release of preliminary safety and efficacy data and final safety and efficacy data from clinical trials; the Company has a sustainable precision oncology pipeline of novel targets; the anticipated

benefits of synthetic lethal drugs; there is a clear path to clinical POC in MTAP -null solid tumors with multiple histologies ; TNG908’s large therapeutic index expected to allow selection of optimal efficacious dose below MTD;

the Company will be pursuing novel combination therapies with inhibitors that have a complementary mechanism of action; poten tial for accelerated regulatory approval of TNG908 in MPNST (and the potential option for a

histology agnostic approval for TNG908); potential for future TNG908 expansion cohorts to evaluate activity in a range of histologies and optionality for multiple registration strategies; one of the largest genetically defined

patient populations may benefit from the PRMT5 franchise; Tango is planning multiple rational combination trials in PRMT5 fra nchise based on strong pre -clinical synergy data; next generation PRMT5 compounds will follow

TNG908 by 12 -18 months; the TNG908 composition of matter patent applications will provide meaningful patent protection through at least 2041; the Company’s belief regarding a strong IP position for USP1 pipeline

product; s ynergy of USP1 in both PARP -sensitive and -resistance models suggests potential to meaningfully expand patient benefit from PARP inhibitor; Tango’s ability to identify, develop and commercialize drug